{"id":66605,"date":"2026-05-28T21:49:07","date_gmt":"2026-05-28T13:49:07","guid":{"rendered":"https:\/\/flcube.com\/?p=66605"},"modified":"2026-05-28T21:49:08","modified_gmt":"2026-05-28T13:49:08","slug":"sciclone-pharmaceuticals-launches-vibativ-in-china-dual-mechanism-glycopeptide-antibiotic-offers-enhanced-mrsa-treatment-with-once-daily-dosing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66605","title":{"rendered":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>SciClone Pharmaceuticals Inc.<\/strong> announced the commercial launch of <strong>Vibativ (telavancin)<\/strong> in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of <strong>hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP)<\/strong> caused by susceptible isolates of <em>Staphylococcus aureus<\/em>, including methicillin-resistant strains (MRSA).<\/p>\n\n\n\n<h2 id=\"h-product-launch-summary\" class=\"wp-block-heading\">Product Launch Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>SciClone Pharmaceuticals Inc. <\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Vibativ (telavancin) \u2013 dual-mechanism glycopeptide antibiotic<\/td><\/tr><tr><td><strong>Launch Market<\/strong><\/td><td>China (commercial launch)<\/td><\/tr><tr><td><strong>Regulatory Approval<\/strong><\/td><td>February 2025 (China)<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>HABP\/VABP caused by susceptible <em>S. aureus<\/em> isolates<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>Theravance Biopharma Inc. (NASDAQ: TBPH)<\/td><\/tr><tr><td><strong>Licensing Agreement<\/strong><\/td><td>May 2021 \u2013 Greater China and Vietnam rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-molecular-innovation-amp-clinical-advantages\" class=\"wp-block-heading\">Molecular Innovation &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Antibacterial Mechanism:<\/strong><\/li>\n\n\n\n<li>Inhibits bacterial cell wall synthesis (shared with vancomycin)<\/li>\n\n\n\n<li>Binds to bacterial cell membranes, disrupting membrane barrier function (unique to telavancin)<\/li>\n\n\n\n<li><strong>Spectrum of Activity:<\/strong> Rapidly bactericidal against Gram-positive pathogens, including MRSA<\/li>\n\n\n\n<li><strong>Pharmacokinetic Advantage:<\/strong> Longer half-life enables once-daily dosing versus multiple daily doses for vancomycin<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong> Improved patient compliance, simplified administration, and enhanced clinical convenience<\/li>\n\n\n\n<li><strong>Therapeutic Differentiation:<\/strong> Unique membrane-binding mechanism provides faster bactericidal effect compared to traditional glycopeptides<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-regulatory-amp-commercial-history\" class=\"wp-block-heading\">Global Regulatory &amp; Commercial History<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Approval Timeline<\/th><th>Indications<\/th><th>Commercial Status<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>2009 (initial approval)<\/td><td>\u2022 cSSTI caused by Gram-positive bacteria including MRSA<br>\u2022 HABP\/VABP caused by susceptible <em>S. aureus<\/em><\/td><td>Commercially available<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>February 2025<\/td><td>HABP\/VABP caused by susceptible <em>S. aureus<\/em><\/td><td>Commercial launch (May 2026)<\/td><\/tr><tr><td><strong>Greater China &amp; Vietnam<\/strong><\/td><td>Under SciClone license (2021)<\/td><td>As approved locally<\/td><td>Development and commercialization by SciClone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The licensing agreement with Theravance Biopharma positions SciClone as the exclusive commercial partner for Vibativ across Greater China and Vietnam, representing a strategic expansion of its anti-infective portfolio.<\/p>\n\n\n\n<h2 id=\"h-addressing-critical-unmet-needs-in-hospital-settings\" class=\"wp-block-heading\">Addressing Critical Unmet Needs in Hospital Settings<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Clinical Challenge<\/th><th>Vibativ Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>MRSA Prevalence<\/strong><\/td><td>Potent activity against methicillin-resistant <em>S. aureus<\/em> strains<\/td><\/tr><tr><td><strong>Treatment Complexity<\/strong><\/td><td>Once-daily dosing simplifies hospital administration protocols<\/td><\/tr><tr><td><strong>Therapeutic Efficacy<\/strong><\/td><td>Dual mechanism provides rapid bactericidal action<\/td><\/tr><tr><td><strong>Antibiotic Resistance<\/strong><\/td><td>Novel mechanism may overcome limitations of traditional glycopeptides<\/td><\/tr><tr><td><strong>Patient Outcomes<\/strong><\/td><td>Improved compliance potentially translates to better clinical outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Hospital-acquired infections represent a significant burden on healthcare systems globally, with MRSA pneumonia carrying high mortality rates and extended hospital stays.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-impact\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Anti-Infective Market:<\/strong> Growing demand for novel antibiotics addressing multidrug-resistant pathogens<\/li>\n\n\n\n<li><strong>Hospital Formulary Access:<\/strong> Targeted at intensive care units, respiratory wards, and infectious disease departments<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Differentiated positioning against vancomycin and other glycopeptide antibiotics<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium pricing justified by clinical advantages and once-daily convenience<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Successful launch supports SciClone&#8217;s strategy of acquiring and commercializing innovative therapies in China<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding SciClone Pharmaceuticals&#8217; Vibativ commercial prospects in China, including market adoption, formulary acceptance, and competitive positioning. Actual results may differ due to risks including pricing pressures, hospital procurement dynamics, competitive developments, and evolving antimicrobial stewardship guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[932,40,152],"class_list":["post-66605","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-6600","tag-market-launch","tag-sciclone-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66605\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing\" \/>\n<meta property=\"og:description\" content=\"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66605\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:49:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:49:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing\",\"datePublished\":\"2026-05-28T13:49:07+00:00\",\"dateModified\":\"2026-05-28T13:49:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 6600\",\"Market launch\",\"SciClone Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66605#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66605\",\"name\":\"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:49:07+00:00\",\"dateModified\":\"2026-05-28T13:49:08+00:00\",\"description\":\"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\\\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66605\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66605#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing - Insight, China&#039;s Pharmaceutical Industry","description":"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66605","og_locale":"en_US","og_type":"article","og_title":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing","og_description":"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).","og_url":"https:\/\/flcube.com\/?p=66605","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:49:07+00:00","article_modified_time":"2026-05-28T13:49:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66605#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66605"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing","datePublished":"2026-05-28T13:49:07+00:00","dateModified":"2026-05-28T13:49:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66605"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 6600","Market launch","SciClone Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66605#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66605","url":"https:\/\/flcube.com\/?p=66605","name":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:49:07+00:00","dateModified":"2026-05-28T13:49:08+00:00","description":"SciClone Pharmaceuticals Inc. announced the commercial launch of Vibativ (telavancin) in China, following its regulatory approval in February 2025. The rapidly bactericidal glycopeptide antibiotic is indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) caused by susceptible isolates of Staphylococcus aureus, including methicillin-resistant strains (MRSA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66605#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66605"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66605#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SciClone Pharmaceuticals Launches Vibativ in China \u2013 Dual-Mechanism Glycopeptide Antibiotic Offers Enhanced MRSA Treatment with Once-Daily Dosing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66605"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66605\/revisions"}],"predecessor-version":[{"id":66609,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66605\/revisions\/66609"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}